- Home
- AES vs ROIV Comparison
AES vs ROIV Comparison
Compare AES & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AES | ROIV |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 25.1B |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AES | ROIV |
|---|---|---|
| Price | $14.81 | $41.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | $15.29 | ★ $28.94 |
| AVG Volume (30 Days) | 6.2M | ★ 7.6M |
| Earning Date | 05-01-2026 | 05-28-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.28 | N/A |
| Revenue | ★ $12,233,000,000.00 | $8,260,000.00 |
| Revenue This Year | $5.22 | N/A |
| Revenue Next Year | $4.81 | $744.61 |
| P/E Ratio | $11.59 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.33 | $13.82 |
| 52 Week High | $17.65 | $42.50 |
Technical Indicators
Market Signals| Indicator | AES | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 61.42 | 72.41 |
| Support Level | $14.64 | $27.15 |
| Resistance Level | $14.88 | N/A |
| Average True Range (ATR) | 0.05 | 1.35 |
| MACD | 0.01 | 0.14 |
| Stochastic Oscillator | 80.00 | 88.42 |
Price Performance
Historical ComparisonAbout AES The AES Corporation
AES is a global power company that operates in 15 countries. Its generation portfolio totals over 32 gigawatts, including renewable energy, gas, coal, and oil. AES has majority ownership in and operates numerous electric utilities.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.